ClinicalTrials.gg
Active, not recruitingNCT05968391RENO-TEPUpdated Oct 22, 2026

Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP)

An observational study in Kidney Failure, Chronic, sponsored by Université de Sherbrooke. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Université de Sherbrooke · Observational

How we know

Updated Oct 22, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.

Planned enrollment
22nd of 24
15 · median 109
Started
2024
with 7 others
Observational
24 of 134
2 open now
Primary completion
2026-12
later than 8 of 27 live
Registered
119th of 134
by date

Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 22nd largest by planned enrollment of the 24 observational ones that give a count, is one of 8 that started in 2024, is one of 24 observational ones, reaches primary completion later than 8 of the 27 other live ones, and was the 119th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Kidney Failure, Chronic with a site in Canada, or all of them as a file.
02

Study summary

The objective of this study is to nake a comparison between 11c-acetate and 11c-acetoacetate kidney uptake in chronic kidney failure patients.

Read the detailed description

Chronic kidney failure patients will be ask to perform two positron emission tomography scan during the same day. One, with a 11C-Acetate Tracer and the other with 11C-Acetoacetate. The results will allow to determine the difference between the two tracers and will ultimately be compared with precedent results of healthy controls.

03

Conditions studied

  • Kidney Failure, Chronic

Keywords

  • ketone
  • acetoacetate
  • acetate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

People with kidney failure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.5 and 40
  • Kidney failure if betweem 30 and 60 mL/min/1.73m2
  • Stable medication for at least 4 weeks

Exclusion criteria

Exclusion Criteria:

  1. Receive cytotoxic therapy for primary or secondary kidney disease within 6 months prior to enrollment
  2. Organ Transplant History
  3. Class IV congestive heart failure ()
  4. Myocardial infarction, unstable angina, stroke or within 12 weeks prior to enrollment
  5. Coronary revascularization (percutaneous coronary intervention or arterial bypass) or valve repair/replacement within 12 weeks of enrollment or is scheduled to undergo one of these procedures within 4 weeks of enrollment
  6. Any condition outside the realm of renal and cardiovascular disease, such as, but not limited to, , with a of less than 2 years in the clinical judgment of the investigator
  7. Active malignancy requiring treatment at Visit 1 (except successfully treated basal or squamous cell carcinoma).
  8. Hepatic impairment ( or alanine transaminase >3x ; or total >2x upper limit of normal at time of enrollment
  9. Pregnancy or lactation
  10. Adherence to a ketogenic diet, consumption of ketogenic products or supplements or intermittent fasting or other diet or supplements that may significantly increase ketones in the past two months.
  11. Daily alcohol consumption >2 servings per day
  12. Participation in other interventional research projects concurrently or participation in other PET research projects in the last year, which exceeds the recommended limits
  13. Inability to lie still in supine position;
  14. Medical fluid restriction limiting fluid intake for the procedure
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Chronic kidney failure

    No interventions for the purpose of the study. They will simply undergo two PET scans consecutively

    Radiation: PET scan metabolic day

Interventions

  • RadiationPET scan metabolic day

    11C-Acetate and 11C-Acetoacetate PET scans

06

What researchers measure

Primary outcomes

  1. Mean in kidney acetate uptake

    Kidney acetate uptake measured by pet scan

    Time frame: 30 minutes

  2. Mean in kidney acetoacetate uptake

    Kidney acetoacetate uptake measured by pet scan

    Time frame: 30 minutes

  3. Mean in kidney acetoacetate metabolism

    Kidney acetoacetate metabolism measured by pet scan

    Time frame: 30 minutes

  4. Mean in kidney acetate metabolism

    Kidney acetate metabolism measured by pet scan

    Time frame: 30 minutes

Secondary outcomes

  1. Mean in heart ejection fraction

    Ejection fraction measured by pet scan

    Time frame: 30 minutes

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 34 months is above that.

Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2024 → Dec 2026 and completion Jun 2025 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Aug 1, 2023
StartActual
Feb 2, 2024
Primary completionEst.
Dec 15, 2026was Dec 2024
CompletionEst.
Feb 15, 2027was Jun 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 22, 2026
Primary completion
Dec 15, 2024→Dec 15, 2026
Oct 22, 2026
Study completion
Jun 15, 2025→Feb 15, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 15, 2024→Dec 15, 2026
    Study completion Jun 15, 2025→Feb 15, 2027
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05968391
Collaborators
Nestle Health Science
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Feb 2, 2024
Primary completion
Dec 15, 2026 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Mélanie Godin, MD
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion